JP2023058590A5 - - Google Patents

Download PDF

Info

Publication number
JP2023058590A5
JP2023058590A5 JP2023017271A JP2023017271A JP2023058590A5 JP 2023058590 A5 JP2023058590 A5 JP 2023058590A5 JP 2023017271 A JP2023017271 A JP 2023017271A JP 2023017271 A JP2023017271 A JP 2023017271A JP 2023058590 A5 JP2023058590 A5 JP 2023058590A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
poly
heavy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023017271A
Other languages
English (en)
Japanese (ja)
Other versions
JP7597836B2 (ja
JP2023058590A (ja
Filing date
Publication date
Priority claimed from JP2019539277A external-priority patent/JP7227138B2/ja
Application filed filed Critical
Publication of JP2023058590A publication Critical patent/JP2023058590A/ja
Publication of JP2023058590A5 publication Critical patent/JP2023058590A5/ja
Priority to JP2024205967A priority Critical patent/JP2025028981A/ja
Application granted granted Critical
Publication of JP7597836B2 publication Critical patent/JP7597836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023017271A 2017-01-20 2023-02-08 骨標的抗体 Active JP7597836B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024205967A JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762448763P 2017-01-20 2017-01-20
US62/448,763 2017-01-20
JP2019539277A JP7227138B2 (ja) 2017-01-20 2018-01-19 骨標的抗体
PCT/US2018/014350 WO2018136698A2 (en) 2017-01-20 2018-01-19 Bone-targeting antibodies

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2019539277A Division JP7227138B2 (ja) 2017-01-20 2018-01-19 骨標的抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024205967A Division JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Publications (3)

Publication Number Publication Date
JP2023058590A JP2023058590A (ja) 2023-04-25
JP2023058590A5 true JP2023058590A5 (cg-RX-API-DMAC7.html) 2023-06-13
JP7597836B2 JP7597836B2 (ja) 2024-12-10

Family

ID=61581744

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019539277A Active JP7227138B2 (ja) 2017-01-20 2018-01-19 骨標的抗体
JP2023017271A Active JP7597836B2 (ja) 2017-01-20 2023-02-08 骨標的抗体
JP2024205967A Pending JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2019539277A Active JP7227138B2 (ja) 2017-01-20 2018-01-19 骨標的抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024205967A Pending JP2025028981A (ja) 2017-01-20 2024-11-27 骨標的抗体

Country Status (17)

Country Link
US (3) US10844115B2 (cg-RX-API-DMAC7.html)
EP (1) EP3571226A2 (cg-RX-API-DMAC7.html)
JP (3) JP7227138B2 (cg-RX-API-DMAC7.html)
KR (3) KR102613463B1 (cg-RX-API-DMAC7.html)
CN (2) CN111032690B (cg-RX-API-DMAC7.html)
AR (1) AR110755A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018210270A1 (cg-RX-API-DMAC7.html)
BR (1) BR112019013986A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050884A1 (cg-RX-API-DMAC7.html)
IL (2) IL317592A (cg-RX-API-DMAC7.html)
MX (2) MX2019008549A (cg-RX-API-DMAC7.html)
MY (2) MY207919A (cg-RX-API-DMAC7.html)
SG (1) SG11201906663VA (cg-RX-API-DMAC7.html)
TW (3) TWI788321B (cg-RX-API-DMAC7.html)
UY (1) UY37576A (cg-RX-API-DMAC7.html)
WO (1) WO2018136698A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907673B (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
EP3796941A4 (en) 2018-05-30 2022-12-28 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
BR112021000065A2 (pt) * 2018-07-10 2021-04-06 Sanofi Terapias de combinação contra câncer direcionando cd38 e tgf-beta
CA3120216A1 (en) * 2018-11-19 2020-05-28 Biocartis Nv Enhanced detection of low-copy-number nucleic acids in an integrated workflow
KR20240018471A (ko) 2021-05-07 2024-02-13 베이롤 칼리지 오브 메드신 중등증 내지 중증 불완전 골형성증의 치료
CN117999093A (zh) * 2021-07-20 2024-05-07 威廉马歇莱思大学 用于骨靶向治疗的经改造组合物
US20230144192A1 (en) 2021-11-01 2023-05-11 Genzyme Corporation Treatment of osteogenesis imperfecta
CN115403657A (zh) * 2022-06-23 2022-11-29 浙江大学 一种TGF-β3生长因子的亲和多肽及其应用
EP4673179A1 (en) 2023-02-27 2026-01-07 William Marsh Rice University Bone-directed therapeutics for the treatment of cancer
JP7479537B1 (ja) * 2023-03-31 2024-05-08 ナガヨシ製薬株式会社 咳を止め、痰を減らし、免疫力を向上させるイナゴマメ多糖類およびその調製方法と使用
WO2025184427A1 (en) * 2024-02-27 2025-09-04 Osteologic Therapeutics, Inc. Bone-targeted antibodies and methods of use thereof
CN120647762B (zh) * 2025-06-16 2026-01-23 首都医科大学附属北京友谊医院 一种抗β1-AR-ECII抗体及其应用
CN120535618B (zh) * 2025-07-28 2025-09-23 成都大熊猫繁育研究基地 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4867973A (en) 1984-08-31 1989-09-19 Cytogen Corporation Antibody-therapeutic agent conjugates
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
ATE239041T1 (de) 1996-02-09 2003-05-15 Basf Ag Humane antikörper welche an humanen tnfalpha binden
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
EP1074563A1 (en) * 1999-08-02 2001-02-07 F. Hoffmann-La Roche Ag Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof
US20030224501A1 (en) 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
KR20050094832A (ko) * 2002-12-31 2005-09-28 알투스 파마슈티컬스 인코포레이티드 단백질 결정과 이온성 중합체를 함유하는 복합체
JP2006525362A (ja) 2003-04-30 2006-11-09 ジェンザイム コーポレーション 腎機能不全を治療するためのTGF−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用
WO2005010049A2 (en) 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
CN1961003B (zh) 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
PL1759001T3 (pl) 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
CA2597098C (en) 2005-02-08 2016-08-02 Steven R. Ledbetter Antibodies to tgfbeta
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
CA2632799A1 (en) * 2005-12-23 2007-07-05 Eli Lilly And Company Tgf-beta binding compositions
AU2008255352B2 (en) 2007-05-31 2014-05-22 Genmab A/S Stable IgG4 antibodies
EA021967B1 (ru) * 2008-01-03 2015-10-30 Дзе Скриппс Рисерч Инститьют Доставка антител посредством модульного домена распознавания
US8574577B2 (en) * 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010072691A1 (en) * 2008-12-22 2010-07-01 Novo Nordisk A/S Antibodies against tissue factor pathway inhibitor
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
US8993524B2 (en) 2010-03-05 2015-03-31 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
EP2714735B1 (en) 2011-06-03 2021-07-21 XOMA Technology Ltd. Antibodies specific for tgf-beta
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
KR20140084201A (ko) * 2011-10-19 2014-07-04 알렉시온 파마 홀딩 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US10052366B2 (en) * 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
MX361773B (es) * 2012-05-31 2018-12-17 Innate Pharma Agentes de ligación a tlr3.
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CA2886607A1 (en) 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
AU2014235933B2 (en) * 2013-03-20 2019-01-24 Baylor College Of Medicine Methods for treating osteogenesis imperfecta
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
SMT202300039T1 (it) 2013-09-13 2023-03-17 Beigene Switzerland Gmbh Anticorpi anti-pd1 e loro uso come terapia e per diagnostica
ES2763429T5 (es) 2013-12-17 2023-06-21 Hoffmann La Roche Procedimientos de tratamiento de cánceres usando antagonistas de la unión al eje de PD-1 y taxanos
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
EP3119419B1 (en) * 2014-03-17 2019-04-03 Piotr Jachimczak Combination for use in a method of treating cancer
CN107428825A (zh) 2014-10-10 2017-12-01 创祐生技股份有限公司 治疗及/或预防肿瘤生长、侵袭及/或转移的方法
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗pd-1抗體類和使用彼等之方法
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
ES2820768T3 (es) 2015-04-03 2021-04-22 Xoma Technology Ltd Tratamiento del cáncer usando inhibidores de TGF-beta y PD-1
HRP20201334T1 (hr) 2015-04-17 2020-11-27 Bristol-Myers Squibb Company Kompozicije koje sadrže kombinaciju ipilimumaba i nivolumaba
WO2017011773A2 (en) * 2015-07-15 2017-01-19 Modernatx, Inc. Codon-optimized nucleic acids encoding antibodies
US20200231652A1 (en) * 2015-08-31 2020-07-23 National Research Council Of Canada Tgf-b-receptor ectodomain fusion molecules and uses thereof
US20190216943A1 (en) * 2016-08-11 2019-07-18 Precithera, Inc. Tgf-beta antagonist conjugates
AR110755A1 (es) * 2017-01-20 2019-05-02 Genzyme Corp Anticuerpos dirigidos a hueso
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途

Similar Documents

Publication Publication Date Title
JP2020505919A5 (cg-RX-API-DMAC7.html)
JP7547581B2 (ja) 腫瘍治療薬及びその応用
KR101522954B1 (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
JP4011914B2 (ja) キメラポリペプチド、その製造方法、およびその使用
Plückthun et al. New protein engineering approaches to multivalent and bispecific antibody fragments
CN101445559B (zh) 三聚体可溶抗体与其产生及使用的方法
JP2021087433A5 (cg-RX-API-DMAC7.html)
JP2024532485A5 (cg-RX-API-DMAC7.html)
JP2018502050A5 (cg-RX-API-DMAC7.html)
CN113195530B (zh) 抗体融合蛋白、制备方法及其应用
FI3820894T3 (fi) Mesoteliinia ja vastaavasti cd137:ää sitovia molekyylejä
JP2023509212A5 (cg-RX-API-DMAC7.html)
Goel et al. Relative position of the hexahistidine tag effects binding properties of a tumor-associated single-chain Fv construct
WO2002033072A1 (fr) Anticorps degrade, agoniste de tpo
CN101981053A (zh) 聚乙二醇化的AβFAB
CN110234355A (zh) 单体人IgG1 Fc和双特异性抗体
CN105377893A (zh) 三聚体抗原结合分子
JP2023544211A5 (cg-RX-API-DMAC7.html)
JP2023530663A5 (cg-RX-API-DMAC7.html)
JP2026004299A5 (cg-RX-API-DMAC7.html)
JP2018512124A5 (cg-RX-API-DMAC7.html)
JP2022542670A5 (cg-RX-API-DMAC7.html)
JP2023552462A5 (cg-RX-API-DMAC7.html)
JPWO2022224997A5 (cg-RX-API-DMAC7.html)
JP2019505565A5 (cg-RX-API-DMAC7.html)